» Articles » PMID: 23483908

High-throughput Massively Parallel Sequencing for Fetal Aneuploidy Detection from Maternal Plasma

Abstract

Background: Circulating cell-free (ccf) fetal DNA comprises 3-20% of all the cell-free DNA present in maternal plasma. Numerous research and clinical studies have described the analysis of ccf DNA using next generation sequencing for the detection of fetal aneuploidies with high sensitivity and specificity. We sought to extend the utility of this approach by assessing semi-automated library preparation, higher sample multiplexing during sequencing, and improved bioinformatic tools to enable a higher throughput, more efficient assay while maintaining or improving clinical performance.

Methods: Whole blood (10mL) was collected from pregnant female donors and plasma separated using centrifugation. Ccf DNA was extracted using column-based methods. Libraries were prepared using an optimized semi-automated library preparation method and sequenced on an Illumina HiSeq2000 sequencer in a 12-plex format. Z-scores were calculated for affected chromosomes using a robust method after normalization and genomic segment filtering. Classification was based upon a standard normal transformed cutoff value of z = 3 for chromosome 21 and z = 3.95 for chromosomes 18 and 13.

Results: Two parallel assay development studies using a total of more than 1900 ccf DNA samples were performed to evaluate the technical feasibility of automating library preparation and increasing the sample multiplexing level. These processes were subsequently combined and a study of 1587 samples was completed to verify the stability of the process-optimized assay. Finally, an unblinded clinical evaluation of 1269 euploid and aneuploid samples utilizing this high-throughput assay coupled to improved bioinformatic procedures was performed. We were able to correctly detect all aneuploid cases with extremely low false positive rates of 0.09%, <0.01%, and 0.08% for trisomies 21, 18, and 13, respectively.

Conclusions: These data suggest that the developed laboratory methods in concert with improved bioinformatic approaches enable higher sample throughput while maintaining high classification accuracy.

Citing Articles

Early childhood growth and nutritional status in India: trends in five National Family Health Surveys spanning 1992 and 2021.

Kundu R, Liczbinska G, Gautam R, Bharati S, Pal M, Bharati P Eur J Clin Nutr. 2025; .

PMID: 39870858 DOI: 10.1038/s41430-025-01568-3.


Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer.

Turriff A, Annunziata C, Malayeri A, Redd B, Pavelova M, Goldlust I N Engl J Med. 2025; 391(22):2123-2132.

PMID: 39774314 PMC: 11711700. DOI: 10.1056/NEJMoa2401029.


Prenatal cfDNA Screening for Emanuel Syndrome and Other Unbalanced Products of Conception in Carriers of the Recurrent Balanced Translocation t(11;22): One Laboratory's Retrospective Experience.

Soster E, Dyr B, Caldwell S, Sussman A, Magharyous H Genes (Basel). 2023; 14(10).

PMID: 37895273 PMC: 10606745. DOI: 10.3390/genes14101924.


Laboratory performance of genome-wide cfDNA for copy number variants as compared to prenatal microarray.

Soster E, Tynan J, Gibbons C, Meschino W, Wardrop J, Almasri E Mol Cytogenet. 2023; 16(1):10.

PMID: 37301962 PMC: 10257834. DOI: 10.1186/s13039-023-00642-4.


Positive cfDNA screening results for 22q11.2 deletion syndrome-Clinical and laboratory considerations.

Soster E, Dyr B, Rafalko J, Almasri E, Cacheris P Front Genet. 2023; 14:1146669.

PMID: 36968594 PMC: 10036386. DOI: 10.3389/fgene.2023.1146669.


References
1.
Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

2.
Patsalis P, Tsaliki E, Koumbaris G, Karagrigoriou A, Velissariou V, Papageorgiou E . A new non-invasive prenatal diagnosis of Down syndrome through epigenetic markers and real-time qPCR. Expert Opin Biol Ther. 2012; 12 Suppl 1:S155-61. DOI: 10.1517/14712598.2012.674108. View

3.
Papageorgiou E, Karagrigoriou A, Tsaliki E, Velissariou V, Carter N, Patsalis P . Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med. 2011; 17(4):510-3. PMC: 3977039. DOI: 10.1038/nm.2312. View

4.
Jensen T, Dzakula Z, Deciu C, Van Den Boom D, Ehrich M . Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem. 2012; 58(7):1148-51. DOI: 10.1373/clinchem.2011.180794. View

5.
Nygren A, Dean J, Jensen T, Kruse S, Kwong W, Van Den Boom D . Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem. 2010; 56(10):1627-35. DOI: 10.1373/clinchem.2010.146290. View